Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of FOLFIRINOX + panitumumab versus mFOLFOX6 + panitumumab in metastatic colorectal cancer
2016-001490-33Phase 2Active
- Sponsor
- Unicancer
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of panitumumab in colorectal cancer (CRC) (2 arms), sponsored by Unicancer. Primary endpoint: Complete response rate. Started Nov 2016; status: active.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2016-001490-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001490-33.